Photo of a clean colon

MoviPrep FAQs

Find out more about MoviPrep

How does MoviPrep work?

MoviPrep is an osmotic laxative with electrolytes that produces a watery stool leading to colon cleansing.1

What are the active ingredients of MoviPrep?

PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid.1

Is MoviPrep proven for effective colon cleansing?

MoviPrep had excellent or good overall colon cleansing when administered with a PM|AM split-dosing regimen.1

Effectiveness of Overall Colon Cleansing in the Study of MoviPrep vs 4–Liter Polyethylene Glycol Plus Electrolytes Solution

Responders
A or B (%)
C§ (%) D|| (%)
MoviPrep
(N=153)
88.9 9.8 1.3
4L PEG + E*
(N=155)
94.8 4.5 0.6

*4L PEG + E is 4-liter polyethylene glycol plus electrolytes solution.
A: Colon empty and clean or presence of clear liquid, but easily removed by suction.
B: Brown liquid or semisolid remaining amounts of stool, fully removable by suction or displaceable, thus allowing a complete visualization of the gut mucosa.
§C: Semisolid amounts of stool, only partially removable with a risk of incomplete visualization of the gut mucosa.
||D: Semisolid or solid amounts of stool; consequently colonoscopy incomplete or needed to be terminated.
4-L PEG+E's responder rate was not significantly higher than MoviPrep's responder rate.

What are the adverse events associated with MoviPrep?

Most common adverse reactions for split dosing (incidence ≥5%) are malaise, nausea, abdominal pain, vomiting, and upper abdominal pain. The most common adverse reactions for evening-only dosing (incidence ≥5%) are abdominal distension, anal discomfort, thirst, nausea, abdominal pain, sleep disorder, rigors, hunger, malaise, vomiting, and dizziness.1

What are the contraindications and warnings/precautions for MoviPrep?

MoviPrep is contraindicated in patients with gastrointestinal (GI) obstruction, bowel perforation, gastric retention, ileus, toxic colitis or toxic megacolon, and patients who have had a severe hypersensitivity reaction to any of its components. MoviPrep should be used with caution in patients at risk of or with fluid and electrolyte abnormalities, hyponatremia, arrhythmias, seizures, in patients with impaired renal function or patients taking concomitant medications that affect renal function, patients with known or suspected inflammatory bowel disease, patients with suspected GI obstruction or perforation, patients at risk for aspiration, and patients with glucose-6-phosphate dehydrogenase deficiency. MoviPrep contains 233 mg of phenylalanine per treatment.1

How is MoviPrep prepared?

MoviPrep solution is prepared by mixing the ingredients provided and adding 1 L of lukewarm water (a suitable container is necessary). Mix the solution to ensure that the ingredients are completely dissolved (if the patient prefers, the MoviPrep solution can be refrigerated prior to drinking, but should be used within 24 hours). After consumption of the first liter of MoviPrep, the above mixing procedure should be repeated with the rest of the ingredients to reconstitute the second liter of the MoviPrep solution.1

Which liquids can my patients drink?

Any clear liquid of their choice is appropriate, such as1

  • water
  • clear fruit juices without pulp including apple, white grape, or white cranberry
  • strained limeade or lemonade
  • coffee or tea (Do not use any dairy or non-dairy creamer)
  • clear broth
  • clear soda
  • gelatin (without added fruit or topping)
  • popsicles (without pieces of fruit or fruit pulp)

Is MoviPrep indicated for adults and children?

MoviPrep is indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. The safety and effectiveness of MoviPrep in pediatric patients has not been established.1

How does split dosing affect the bowel prep experience of the patient?

A study showed that the percentage of patients who required a bathroom stop in transit to their colonoscopy was similar with both split-dose and evening-only regimens.2 In a survey, 78% of patients scheduled for morning colonoscopy followed instructions and rose in the middle of the night to take the AM dose.3 Finally, in a comparative study, patients taking split-dose formulation were more often satisfied with the bowel preparation than those who took the bowel prep entirely the evening before.2 In fact, 9 out of 10 MoviPrep patients say they would take MoviPrep again.4

Does the American College of Gastroenterology (ACG) recommend split dosing?

Yes, since 2008 the ACG has recommended split dosing for bowel preps.5

View the ACG Guidelines Recommendations pdf icon

Indication for MOVIPREP

MOVIPREP® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older.

Important Safety Information about MOVIPREP

MOVIPREP® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) is contraindicated in patients with gastrointestinal (GI) obstruction, bowel perforation, gastric retention, ileus, toxic colitis or toxic megacolon, and patients who have had a hypersensitivity reaction to any of its components.

Patients must be advised to hydrate adequately before, during, and after the use of MOVIPREP. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment. MOVIPREP should be used with caution in patients using concomitant medications that increase the risk of electrolyte abnormalities or in patients with known or suspected hyponatremia. Consider laboratory assessments prior to and after use.

In patients with impaired renal function or patients taking concomitant medications that affect renal function, use MOVIPREP with caution, ensure adequate hydration, and consider testing.

In patients with suspected GI obstruction or perforation, rule out the diagnosis before administration of MOVIPREP.

Patients with impaired gag reflex and patients prone to regurgitation or aspiration should be observed during the administration of MOVIPREP.

Use MOVIPREP with caution in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Patients should be advised that MOVIPREP contains 131 mg of phenylalanine per treatment.

Animal reproduction studies have not been performed. MOVIPREP should only be given to a pregnant woman if clearly needed.

Most common adverse reactions for split dosing (incidence ≥ 5%) are malaise, nausea, abdominal pain, vomiting, and upper abdominal pain. The most common adverse reactions for evening only dosing (incidence ≥ 5%) are abdominal distension, anal discomfort, thirst, nausea, abdominal pain, sleep disorder, rigors, hunger, malaise, vomiting, and dizziness.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch/ or call 1-800-FDA-1088.

For product information, adverse event reports, and product complaint reports, please contact:

Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email: salix@medcomsol.com

Please see complete Prescribing Information for MOVIPREP. pdf icon

For Dummies is a registered trademark of John Wiley & Sons, Inc.

References: 1. MoviPrep [prescribing information]. Raleigh, NC. Salix Pharmaceuticals, Inc; 2013. 2. Khan MA, Piotrowski Z, Brown MD. Patient acceptance, convenience, and efficacy of single-dose versus split-dose colonoscopy bowel preparation J Clin Gastroenterol. 2010;44:310-311. 3. Unger RZ, Amstutz SP, Seo da H, Huffman M, Rex DK. Willingness to undergo split-dose bowel preparation for colonoscopy and compliance with split-dose instructions. Dig Dis Sci. 2010;55:2030-2034. 4. Ponchon T, Boustiere C, Heresbach D, et al. A low-volume polyethylene glycol plus ascorbate solution for bowel cleansing prior to colonoscopy: the NORMO randomised clinical trial [published online ahead of print June 13, 2013]. Dig Liver Dis. doi: 10,1016/j.dld.2013.04.009. 5. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology guidelines for colorectal cancer screening 2008. Am J Gastroenterol. 2009;104:739-750.

Use of this site signifies your agreement to the Terms of Use. Privacy Policy.
©2014 Salix Pharmaceuticals, Inc. All rights reserved. MOV 13/22
8510 Colonnade Center Drive, Raleigh, NC 27615 USA T: 919-862-1000, F: 919-862-1095